, Volume 29, Issue 5, pp 130-134

Rotavirus vaccine RIX4414 (Rotarix®): a guide to its use in preventing rotavirus gastroenteritis in the EU

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

The human monovalent rotavirus vaccine RIX4414 (Rotarix®) is indicated for the prevention of rotavirus gastroenteritis (RVGE) in infants aged 6 to 24 weeks in the EU. It offers broad sustained protective efficacy against RVGE including severe cases, and reduces the incidence of associated hospitalizations. It does not interfere with the immunogenicity of other paediatric vaccinations, and is considered safe.